{
  "items": "8",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "AEON Biopharma Announces Exchange Agreement with Daewoong",
      "url": "https://www.tipranks.com/news/company-announcements/aeon-biopharma-announces-exchange-agreement-with-daewoong",
      "time_published": "20251216T210901",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "AEON Biopharma has announced an Exchange Agreement with Daewoong Pharmaceuticals. This agreement involves exchanging previously issued convertible notes for common stock, a new convertible note, and warrants, and is subject to stockholder approval. Spark, TipRanks' AI Analyst, rates AEON as an Underperform due to significant financial distress, negative profitability, and cash flow challenges, despite some technical stabilization.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_390599908-1-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915918"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.841173"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.720788"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.619946"
        },
        {
          "topic": "finance",
          "relevance_score": "0.612108"
        }
      ],
      "overall_sentiment_score": -0.412221,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.405466",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "AEON Biopharma signs Daewoong note exchange with equity and warrants | AEON SEC Filing - Form 8-K",
      "url": "https://www.stocktitan.net/sec-filings/AEON/8-k-aeon-biopharma-inc-reports-material-event-82f40907f584.html",
      "time_published": "20251215T211450",
      "authors": [],
      "summary": "AEON Biopharma has entered into an Exchange Agreement with Daewoong to convert Daewoong's existing senior secured convertible notes into equity, a new $1.5 million senior secured convertible note, and warrants. This exchange is expected to result in approximately 23.1 million newly issued shares or pre-funded warrants, with Daewoong's ownership capped at 49.99%. The new convertible note features a 15.79% annual interest rate and automatic conversion into equity under specific financing conditions, while the transaction requires stockholder approval.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.817615"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.729197"
        },
        {
          "topic": "finance",
          "relevance_score": "0.736910"
        }
      ],
      "overall_sentiment_score": 0.137216,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.147059",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AEON Biopharma (NYSE: AEON) agrees Daewoong swap cutting over 90% of debt",
      "url": "https://www.stocktitan.net/news/AEON/aeon-biopharma-announces-execution-of-exchange-agreement-with-tolwp9o8uacx.html",
      "time_published": "20251215T210950",
      "authors": [
        "NULL"
      ],
      "summary": "AEON Biopharma announced a definitive exchange agreement with Daewoong to convert $15 million in convertible notes and accrued interest into new equity, $1.5 million in new notes due 2030, and cash-exercise warrants for 8 million common shares. This transaction, which is subject to stockholder approval, is expected to eliminate over 90% of AEON\u2019s outstanding debt and could provide more than $8 million in additional cash if the warrants are exercised. The deal aims to strengthen Daewoong\u2019s strategic alignment with AEON and significantly transform AEON's capital structure.",
      "banner_image": "https://ml.globenewswire.com/media/MzMyMDg3ZjQtYTE0MS00M2Q2LWE0YjItNGVlMTBjNGQ0YWYyLTEyMzMzMzEtMjAyNS0xMi0xNS1lbg==/tiny/AEON-Biopharma-Inc.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910922"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.848507"
        },
        {
          "topic": "finance",
          "relevance_score": "0.703172"
        }
      ],
      "overall_sentiment_score": 0.408988,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.427274",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AEON - Aeon Biopharma Latest Stock News & Market Updates",
      "url": "https://www.stocktitan.net/news/AEON/",
      "time_published": "20251208T052158",
      "authors": [],
      "summary": "This page provides the latest news and updates for Aeon Biopharma (AEON), a clinical-stage biopharmaceutical company focusing on its proprietary botulinum toxin therapy, ABP-450, for neurological disorders. Recent highlights include PIPE investments, FDA meeting updates for ABP-450 biosimilar development, inducement grants, and management changes. The company is actively pursuing a 351(k) biosimilar regulatory pathway for ABP-450, aiming to enter the therapeutic toxin market.",
      "banner_image": "https://static.stocktitan.net/company-logo/aeon.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.935501"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.840889"
        }
      ],
      "overall_sentiment_score": 0.115877,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.124524",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes",
      "url": "https://www.manilatimes.net/2025/11/13/tmt-newswire/globenewswire/aeon-biopharma-announces-fundraise-totaling-up-to-22-million-through-private-placement-and-proposed-exchange-of-daewoong-convertible-notes/2223282",
      "time_published": "20251113T052158",
      "authors": [
        "GlobeNewswire"
      ],
      "summary": "AEON Biopharma announced two transactions, a private placement and a proposed exchange of Daewoong convertible notes, totaling up to $22 million. These transactions will strengthen the company's balance sheet, reduce outstanding debt by over 90%, and provide capital to accelerate its ABP-450 biosimilar program, including submission of positive analytical data to the FDA. The financing extends AEON's cash runway into Q2 2026, supporting its biosimilar development efforts.",
      "banner_image": "https://ml.globenewswire.com/media/MjM0NWU3YTgtYmMyNi00MmFlLWFmNjctYzhlMzQ2ZTU5YjRkLTEyMzMzMzEtMjAyNS0xMS0xMy1lbg==/tiny/AEON-Biopharma-Inc.png",
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.941960"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.739169"
        }
      ],
      "overall_sentiment_score": 0.454647,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.492854",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AEON Stock Price and Chart \u2014 AMEX:AEON",
      "url": "https://www.tradingview.com/symbols/AMEX-AEON/",
      "time_published": "20251102T114108",
      "authors": [],
      "summary": "This article provides comprehensive financial data and trading information for AEON Biopharma, Inc. (AMEX:AEON), including its stock price performance, key statistics, upcoming earnings, and analyst ratings. It also features a company overview, related stock ideas, and answers to frequently asked questions about the stock.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.939662"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.930321"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.835546"
        }
      ],
      "overall_sentiment_score": 0.068186,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.093633",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AEON Biopharma Inc. Class A (AEON) reports earnings",
      "url": "https://qz.com/aeon-biopharma-inc-class-a-aeon-reports-earnings-1851772053",
      "time_published": "20250324T000000",
      "authors": [
        "Quartz Intelligence Newsroom"
      ],
      "summary": "AEON Biopharma Inc. (AEON) filed its annual 10-K report detailing its focus on developing ABP-450 as a Botox biosimilar, despite discontinuing some migraine trials for cash preservation. The company reported a net income of $42.0 million but acknowledges substantial doubt about its ability to continue as a going concern, highlighting the critical need for additional capital. Key risks include regulatory delays, competition, and reliance on third-party manufacturers, alongside challenges in intellectual property and compliance.",
      "banner_image": null,
      "source": "qz.com",
      "category_within_source": "General",
      "source_domain": "qz.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.916809"
        }
      ],
      "overall_sentiment_score": -0.235486,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.206380",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update",
      "url": "https://www.stocktitan.net/news/AEON/aeon-biopharma-reports-second-quarter-2024-financial-results-and-oggd711033rw.html",
      "time_published": "20240812T160500",
      "authors": [],
      "summary": "AEON Biopharma (NYSE: AEON) announced its second quarter 2024 financial results and provided a corporate update, focusing on the development of ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX\u00ae. The company is progressing with plans to initiate a single pivotal clinical study in cervical dystonia and is scheduled to hold an initial advisory meeting with the FDA in Q3 2024 regarding the 351(k) regulatory pathway. The biosimilar approach offers potential for a single approval covering all of BOTOX's current and future therapeutic indications, aiming for an efficient entry into the U.S. market.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.928134"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.837147"
        }
      ],
      "overall_sentiment_score": 0.482508,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AEON",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.457791",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}